Cramer Backs Abbott’s Exact Sciences Buy, Calling It a Pivotal Diagnostics Move
Cramer says regulatory approval now stands as the key test for Abbott’s diagnostics bet.
Overview
- Abbott announced a cash acquisition of Exact Sciences valued at roughly $21–$23 billion, which Cramer described as the largest healthcare deal in two years and the biggest diagnostics acquisition ever.
- Cramer argued the purchase fills a gap in Abbott’s diagnostics business by adding established cancer-screening products and more consistent recurring revenue.
- He highlighted international growth potential for Exact Sciences under Abbott’s umbrella, calling the tie-up a meaningful accelerator for the company’s growth rate.
- Cramer noted Abbott shares fell more than $6 over two days even though the company is paying in cash, and he recommended buying the stock on that weakness.
- He suggested the deal’s fate hinges on antitrust scrutiny, asserting it could face less resistance under the current administration, while the companies target a Q2 2026 close pending approvals.